[go: up one dir, main page]

DE68928665D1 - Behandlung von gastro-intestinalen krankheiten - Google Patents

Behandlung von gastro-intestinalen krankheiten

Info

Publication number
DE68928665D1
DE68928665D1 DE68928665T DE68928665T DE68928665D1 DE 68928665 D1 DE68928665 D1 DE 68928665D1 DE 68928665 T DE68928665 T DE 68928665T DE 68928665 T DE68928665 T DE 68928665T DE 68928665 D1 DE68928665 D1 DE 68928665D1
Authority
DE
Germany
Prior art keywords
microflora
host
intestinal diseases
treating gastro
abnormal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68928665T
Other languages
English (en)
Other versions
DE68928665T2 (de
Inventor
Thomas Julius Borody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gastro Services Pty Ltd
Original Assignee
Gastro Services Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastro Services Pty Ltd filed Critical Gastro Services Pty Ltd
Publication of DE68928665D1 publication Critical patent/DE68928665D1/de
Application granted granted Critical
Publication of DE68928665T2 publication Critical patent/DE68928665T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE68928665T 1988-08-02 1989-08-02 Behandlung von gastro-intestinalen krankheiten Expired - Fee Related DE68928665T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPI961388 1988-08-02
AUPJ383789 1989-04-21
PCT/AU1989/000328 WO1990001335A1 (en) 1988-08-02 1989-08-02 Treatment of gastro-intestinal disorders

Publications (2)

Publication Number Publication Date
DE68928665D1 true DE68928665D1 (de) 1998-06-10
DE68928665T2 DE68928665T2 (de) 1998-11-12

Family

ID=25643518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68928665T Expired - Fee Related DE68928665T2 (de) 1988-08-02 1989-08-02 Behandlung von gastro-intestinalen krankheiten

Country Status (5)

Country Link
EP (1) EP0433299B1 (de)
AT (1) ATE165738T1 (de)
CA (1) CA1333564C (de)
DE (1) DE68928665T2 (de)
WO (1) WO1990001335A1 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ337505A (en) 1997-02-11 2001-07-27 Univ College Cork Nat Univ Ie Isolated antimicrobial agents from Lactobacillus salivarius
IT1299070B1 (it) * 1998-04-10 2000-02-07 Proge Farm Srl Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
SE523136C2 (sv) * 1999-12-21 2004-03-30 Gottfriesmottagningen Ab Användning av stafylokockbakterier i samband med behandling av irritable bowelsyndrome
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8894991B2 (en) 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
US20050152884A1 (en) 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
CA2609617C (en) 2005-05-31 2014-07-08 The Iams Company Feline probiotic lactobacilli
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
CA2673465A1 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal
NZ585210A (en) 2007-10-26 2012-07-27 Brenda e moore Probiotic compositions comprising bacteroides and methods for inducing and supporting weight loss
CN102940652B (zh) * 2008-05-28 2015-03-25 青岛东海药业有限公司 两形真杆菌制剂及其应用
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
PT3564357T (pt) 2010-02-01 2022-06-14 Rebiotix Inc Bacterioterapia para colite por clostridium difficile
CA2807242C (en) * 2010-08-04 2017-05-02 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
EP2651415B1 (de) 2010-12-13 2020-10-07 Rite-Prep Pty Ltd. Magen/darm-formulierungen sowie verfahren zu ihrer herstellung und verwendung
BR112013022927A2 (pt) 2011-03-09 2016-12-06 Univ Minnesota composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104797244B (zh) 2012-07-27 2018-03-09 红山生物医药有限公司 用于结肠排空的制剂和制备制剂方法
AU2013347805C1 (en) 2012-11-23 2018-06-28 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
EP2951283A4 (de) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Zusammensetzungen und verfahren
AU2014212003C1 (en) 2013-02-04 2020-07-16 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
AU2014232370B2 (en) 2013-03-15 2018-11-01 Société des Produits Nestlé S.A. Network-based microbial compositions and methods
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
WO2014197562A1 (en) 2013-06-05 2014-12-11 Rebiotix, Inc. Microbiota restoration therapy (mrt), compositions and methods of manufacture
WO2015077794A1 (en) 2013-11-25 2015-05-28 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
EP3082431A4 (de) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bakterielle zusammensetzungen und verfahren zur verwendung davon zur behandlung von immunsystemkrankheiten
CN106687130B (zh) * 2014-08-05 2020-01-21 深圳华大基因科技有限公司 真杆菌属在预防和治疗结直肠癌相关疾病中的用途
WO2016019505A1 (en) * 2014-08-05 2016-02-11 Bgi Shenzhen Co., Limited Use of eubacterium in the prevention and treatment for colorectal cancer related diseases
CN104546951B (zh) * 2014-09-30 2019-03-01 深圳华大基因科技有限公司 规则粪球菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
CN113730442A (zh) 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
GB201421735D0 (en) * 2014-12-07 2015-01-21 Craig Nicola M Humanized gut microbiota
SG10201913609PA (en) 2014-12-23 2020-03-30 4D Pharma Res Ltd Immune modulation
SMT201800291T1 (it) 2014-12-23 2018-07-17 4D Pharma Res Limited Polipeptide pirina e modulazione immunitaria
KR20180026376A (ko) 2015-05-14 2018-03-12 크레스토보 홀딩스 엘엘씨 대변 균무리 이식용 조성물, 및 이의 제조 및 사용 방법, 및 이의 전달을 위한 장치
EP3294308A4 (de) 2015-05-14 2019-03-06 University of Puerto Rico Verfahren zur wiederherstellung der biozönose von neugeborenen
HUE058209T2 (hu) 2015-05-22 2022-07-28 Univ Arizona State Módszerek az autizmus spektrum zavar és azzal összefüggõ tünetek kezelésére
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
KR102342925B1 (ko) 2015-06-09 2021-12-23 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(ｍｒｔ) 조성물 및 제조 방법
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
SMT201900539T1 (it) 2015-06-15 2019-11-13 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3360559B1 (de) 2015-06-15 2019-10-23 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
CA3016179C (en) 2016-03-04 2019-08-13 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
WO2018187467A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
TW201907929A (zh) 2017-05-22 2019-03-01 英商4D製藥研究有限公司 包含細菌品系之組成物
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
EP3630190B1 (de) 2017-05-26 2024-02-21 Finch Therapeutics Holdings LLC Lyophilisierte zusammensetzungen, die therapeutische mittel auf der basis von fäkalienmikroben enthalten, und verfahren zu ihrer herstellung und verwendung
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
WO2018229236A2 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
RU2659417C1 (ru) * 2017-06-22 2018-07-02 Федеральное государственное бюджетное научное учреждение "Иркутский научный центр хирургии и травматологии" Устройство для подготовки донорского фекального материала к трансплантации
AU2018313766A1 (en) 2017-08-07 2020-02-20 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
RU2020117775A (ru) 2017-10-30 2021-12-01 Серес Терапеутикс, Инк. Композиции и способы для лечения устойчивости к антибиотикам
EP3476396A1 (de) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bakterien- und zellzusammensetzungen zur behandlung von kolorektalkarzinomen und verfahren zur beurteilung einer prognose für patienten damit
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
EP3823651A4 (de) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. Verfahren und zusammensetzungen zur mikrobiellen transplantation
KR20200021257A (ko) * 2018-08-20 2020-02-28 아주대학교산학협력단 유박테리움 렉탈레를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
CA3147629A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
CN116543899B (zh) * 2023-03-24 2025-08-22 康美华大基因技术有限公司 一种慢性肾病微生物标志物的应用和风险预测模型及其构建方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1275M (fr) * 1961-05-06 1962-05-02 Rene Roger Médicament a base de colibacilles vivants.
BE634858A (de) * 1962-07-19 1900-01-01
FR2828M (fr) * 1963-03-01 1964-11-02 Lucien Nouvel Médicament renfermant des colibacilles antibiorésistants.
FR5528M (de) * 1965-10-01 1967-11-13
GB1271674A (en) * 1968-07-09 1972-04-26 Nisshin Flour Milling Co Process and preparation for treating diarrhoea in pigs
SE371209B (de) * 1969-10-13 1974-11-11 Cernelle Ab
DE2134179A1 (de) * 1971-07-09 1973-01-25 Rolf Dr Schuler Bifidobakterien enthaltendes praeparat und verfahren zur herstellung desselben
FR2244464A1 (en) * 1973-06-26 1975-04-18 Serozym Laboratoires Yeast, lacto- and colibacillus based compsns - used to modify intestinal flora, treat colitis and digestive disorders, etc.
US4335107A (en) * 1978-06-05 1982-06-15 Snoeyenbos Glenn H Mixture to protect poultry from salmonella
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
FI840816A0 (fi) * 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat

Also Published As

Publication number Publication date
EP0433299B1 (de) 1998-05-06
ATE165738T1 (de) 1998-05-15
WO1990001335A1 (en) 1990-02-22
CA1333564C (en) 1994-12-20
EP0433299A4 (en) 1992-04-08
DE68928665T2 (de) 1998-11-12
EP0433299A1 (de) 1991-06-26

Similar Documents

Publication Publication Date Title
DE68928665D1 (de) Behandlung von gastro-intestinalen krankheiten
FI833605A0 (fi) Ny oral mopidamolprodukt
ATE153534T1 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
PT782841E (pt) Dispositivo de introducao para uma protese endoluminal com protese endoluminal
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE3873800D1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
ES2161780T3 (es) Polimeros que ligan fosfato para administracion oral.
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
DE19975006I2 (de) Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler St¦rungen.
EP0744176A3 (de) Arzneimittel zur Hemmung von Knochenschwund
ATE198049T1 (de) Behandlung von magen- und darmgeschwüren mit morphogenen
MX9203208A (es) Composicion farmaceutica y metodo para el tratamiento de trastornos digestivos.
FR2719480B1 (fr) Compositions pharmaceutiques destinées à prévenir et/ou traiter l'expression du comportement de couvaison chez les oiseaux et plus particulièrement chez la dinde et leurs procédés de préparation.
IL124730A0 (en) Compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of gastrointestinal disorders
CA2248753A1 (en) Use of olanzapine for treating excessive aggression
GR3024707T3 (en) Digitoxigenin and dihydrodigitoxigenin 3beta-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
DK32893A (da) Geminale cycloalkyldiphosphonsyrer og farmaceutisk acceptable salte heraf samt farmaceutisk sammensaetning omfattende samme
TR199801043T2 (xx) Mide-ba��rsak bozukluklar�n�n �nlenmesi ve tedavisi i�in bizmut i�eren bile�imler.
DE68901234D1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
IT8919204A0 (it) Composizione per la prevenzione e la cura di parodontopatte.
ATE85750T1 (de) Vorrichtung zur behandlung von verstauchungen, insbesondere der sprunggelenke sowie zur vermeidung von dabei auftretenden bestimmten komplikationen.
RU93035807A (ru) Способ лечения юношеского эпифизиолиса

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee